First-In-Human (FIH) Trial Evaluating the Safety and Tolerability of Single and Multiple Ascending Oral Doses of IRL757 in Healthy Volunteers

Phase 1 Completed 82 enrolled Integrative Research Laboratories AB Michael J. Fox Foundation for Parkinson's Research · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase 1, First-In-Human study evaluating the safety and tolerability of single and multiple ascending oral doses of IRL757 in healthy volunteers.

Timeline

Start: 2024-05-16
Primary completion: 2025-02-07
Completion: 2025-02-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IRL757	Unknown	—	Oral

Indications

No indication recorded.